Drug Trial Radar · NCT05018416
Renal Autologous Cell Therapy (REACT) in Subjects With Type 1 or 2 Diabetes and Chronic Kidney Disease (REGEN-007)
Last checked: Nov 20, 2026Latest source record: Mar 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
53
Actual
Start
Jul 27, 2021
Primary completion
May 20, 2025
Study completion May 20, 2025
Sponsor
- Lead sponsor
- ProkidneyIndustry
- Sponsor type
- Industry
- First posted
- Aug 24, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 30 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety, efficacy, and durability of up to two Renal Autologous Cell Therapy (REACT) / rilparencel injections delivered percutaneously into biopsied and non-biopsied contralateral kidneys on renal function progression in two different cohorts of subjects with Type1 Diabetes Mellitus (T1DM) or Type2 Diabetes Mellitus(T2DM) and Chronic Kidney Disease (CKD).
Conditions
- Chronic Kidney Diseases
- Type 1 Diabetes Mellitus
- Type 2 Diabetes Mellitus
Interventions
Renal Autologous Cell Therapy (REACT)Biological
Autologous selected renal cells (SRC)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Improvement in renal function progression rate as indicated by the change from pre-injection baseline value in total (acute + chronic) slope of estimated glomerular filtration rate (eGFR) using the CKD-EPI 2009 equationTime frame: Screening thru month 28
- Procedural and investigational product-related treatment-emergent adverse events (TEAEs) obtained through 18 months after the last REACT injection.Time frame: Screening thru 18 months after the last injection of study drug
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Kidney Associates of Colorado, P.C. - Frenova
Denver, Colorado
Nephrology Associates
Newark, Delaware
Boise Kidney and Hypertension Institute - Frenova
Nampa, Idaho
Paragon Health, PC d/b/a Nephrology Center, PC - Frenova
Kalamazoo, Michigan
Nephrology and Hypertension Associates Ltd - Frenova
Tupelo, Mississippi
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.